What to know about new diagnostic tools, targeted medications, and other recent advances in the treatment of metastatic NSCLC ...

More than one quarter of the medcines cleared by the FDA’s main review office since 2015 have been cancer drugs, a tally that ...

(NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted ...

A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 5, 2025 /EINPresswire.com/ -- What Is The Projected Market Size Of The Opdivo Nivolumab Market? The Opdivo nivolumab market has seen strong growth in ...